---
audienceLevel: patient
cancerTypes:
- ovarian
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Mirvetuximab Soravtansine-gynx - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/mirvetuximab-soravtansine-gynx
version: v1
---

# Mirvetuximab Soravtansine-gynx - NCI

# Mirvetuximab Soravtansine-gynx

Placeholder slot

(MEER-veh-TUK-sih-mab SOH-rav-TAN-seen)

This page contains brief information about mirvetuximab soravtansine-gynx
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Elahere

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2&audience=consumer)

## Use in Cancer

Mirvetuximab soravtansine-gynx
is approved to treat:

- **[Ovarian epithelial](/Common/PopUps/popDefinition.aspx?id=46768&version=Patient&language=English), [fallopian tube](/Common/PopUps/popDefinition.aspx?id=755773&version=Patient&language=English), or [primary peritoneal cancer](/Common/PopUps/popDefinition.aspx?id=386215&version=Patient&language=English)** that is folate receptorâ€“alpha positive. It is used in adults whose cancer did not respond to or is no longer responding to [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English) chemotherapy and who have received one to three types of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).

Mirvetuximab soravtansine-gynx
is also being studied in the treatment of other types of
cancer.

## More About Mirvetuximab Soravtansine-gynx

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/734941) - Detailed scientific definition and other names for this drug.

## Research Results and Related Resources

[Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers](https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Mirvetuximab Soravtansine](https://www.cancer.gov/research/participate/clinical-trials/intervention/C102566) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
